Jean-Pierre B.
- Country
- France
- Department
- Hépato gastroentérologie
Research Overview
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Efimosfermin Alfa in Adults with Biopsy‑Confirmed F2–F3 Metabolic Dysfunction‑Associated Steatohepatitis
- Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carcinoma, a phase 2b randomized trial. ABE-LIVER
- Phase 3 Randomized Double‑Blind Placebo‑Controlled Study of Efimosfermin Alfa Safety and Tolerability in Adults with F2‑F3 Metabolic Dysfunction‑Associated Steatohepatitis
Data & Insights
Has run more than one trial at 215 of 385 partner sites.
Specializations
Liver Cancer Research
Specializes in investigating advanced treatments for hepatocellular carcinoma, particularly focusing on immunotherapy approaches and combination therapies.
- Novel immunotherapy combinations
- Transarterial chemoembolization (TACE)
- Post-resection recurrence prevention
Explores innovative therapeutic strategies for both localized and advanced stages of liver cancer.
Metabolic Liver Diseases
Conducts research in metabolic dysfunction-associated steatohepatitis and related conditions, with emphasis on novel therapeutic interventions.
- NASH/MASH treatment approaches
- Fibrosis management
- Cirrhosis complications
Investigates breakthrough treatments for progressive liver diseases and their complications.
Cholestatic Liver Diseases
Focuses on therapeutic solutions for primary biliary cholangitis and primary sclerosing cholangitis.
- Cholestasis management
- Bile acid therapeutics
- Adjunctive treatment approaches
Evaluates innovative treatment strategies for chronic cholestatic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.